Contrast Media pp 181-191 | Cite as

Diagnostic Efficacy of Gadolinium-Based Contrast Media

Part of the Medical Radiology book series (MEDRAD)


Since the introduction of gadolinium-based contrast agents, multiple studies have shown that they improve the diagnostic efficacy of MRI significantly. Compared to unenhanced MRI, all agents help to improve the detection and delineation of lesions and so alter the diagnosis in up to 40 % of patients. Doubling or tripling the standard dose of 0.1 mmol kg−1 body weight may be beneficial for particular indications, such as brain perfusion, equivocal single dose MRI study for brain metastasis or small vessel MR angiography. Comparative studies do not show clinically significant differences in diagnostic efficacy between the various extracellular gadolinium-based contrast media. Agents at a higher concentration, or which bind protein, may be relatively more suitable for particular applications, such as dynamic contrast MRI. Gadoxetate disodium provides improved liver diagnosis. It has a primary role in the characterization of benign liver lesions and is an important problem-solving or presurgical tool in the diagnosis and management of liver metastases and hepatocellular carcinoma.


Brain Metastasis Focal Nodular Hyperplasia Double Dose Gadopentetate Dimeglumine Hepatobiliary Phase 


  1. Alegre Castellanos A, Molina Granados JF, Escribano Fernandez J et al (2012) Early phase detection of bile leak after hepatobiliary surgery: value of Gd-EOB-DTPA-enhanced MR cholangiography. Abdom Imaging 37:795–802PubMedGoogle Scholar
  2. Akeson P, Jonsson E, Haugen I, Holtas S (1995) Contrast- enhanced MRI of the central nervous system: comparison between gadodiamide injection and gadolinium-DTPA. Neuroradiology 37:229–233PubMedGoogle Scholar
  3. Anzalone N, Scomazzoni F, Castellano R et al (2005) Carotid artery stenosis: intraindividual correlations of 3D time-offlight MR angiography, contrast-enhanced MR angiography, conventional DSA, and rotational angiography for detection and grading. Radiology 236:204–213PubMedGoogle Scholar
  4. Anzalone N, Gerevini S, Scotti R et al (2009) Detection of cerebral metastases on magnetic resonance imaging: intraindividual comparison of gadobutrol with gadopentetate dimeglumine. Acta Radiol 50:933–940PubMedGoogle Scholar
  5. Anzalone N, Scarabino T, Venturi C et al (2013) Cerebral neoplastic enhancing lesions: multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0 M) and gadoterate meglumine (0.5 M) at 0.1 mmol Gd/kg body weight in a clinical setting. Eur J Radiol 82:139–145PubMedGoogle Scholar
  6. Aslanian V, Lemaignen H, Bunouf P et al (1996) Evaluation of the clinical safety of gadodiamide injection, a new nonionic MRI contrast medium for the central nervous system: a European perspective. Neuroradiology 38:537–541PubMedGoogle Scholar
  7. Attenberger UI, Haneder S, Morelli JN et al (2010) Peripheral arterial occlusive disease: evaluation of a high spatial and temporal resolution 3-T MR protocol with a low total dose of gadolinium versus conventional angiography. Radiology 257(3):879–887PubMedGoogle Scholar
  8. Baek CK, Choi JY, Kim KA et al (2012) Hepatocellular carcinoma in patients with chronic liver disease: a comparison of gadoxetic acid-enhanced MRI and multiphasic MDCT. Clin Radiol 67:148–156PubMedGoogle Scholar
  9. Balériaux D, Matos C, De Greef D (1993) Gadodiamide injection as a contrast medium for MRI of the central nervous system: a comparison with gadolinium-DOTA. Neuroradiology 35:490–494PubMedGoogle Scholar
  10. Balériaux D, Colosimo C, Ruscalleda J et al (2002) Magnetic resonance imaging of metastatic disease to the brain with gadobenate dimeglumine. Neuroradiology 44:191–203PubMedGoogle Scholar
  11. Ball WS Jr, Nadel SN, Zimmerman RA et al (1993) Phase III multicenter clinical investigation to determine the safety and efficacy of gadoteridol in children suspected of having neurologic disease. Radiology 186:769–774PubMedGoogle Scholar
  12. Benner T, Reimer P, Erb G et al (2000) Cerebral MR perfusion imaging: first clinical application of a 1 M gadolinium chelate (Gadovist 1.0) in a double-blinded randomized dose- finding study. J Magn Reson Imaging 12:371–380PubMedGoogle Scholar
  13. Bird CR, Drayer BP, Medina M et al (1988) Gd-DTPA-enhanced MR imaging in pediatric patients after brain tumor resection. Radiology 169:123–126PubMedGoogle Scholar
  14. Brugières P, Gaston A, Degryse HR et al (1994) Randomised double blind trial of the safety and efficacy of two gadolinium complexes (Gd-DTPA and Gd-DOTA). Neuroradiology 36:27–30PubMedGoogle Scholar
  15. Bui BT, Miller S, Mildenberger P et al, Omniscan MRA Investigator Panel (2010) Comparison of contrast-enhanced MR angiography to intraarterial digital subtraction angiography for evaluation of peripheral arterial occlusive disease: results of a phase III multicenter trial. J Magn Reson Imaging 31:1402–1410Google Scholar
  16. Carvlin MJ, De Simone DN, Meeks MJ (1992) Phase II clinical trial of gadoteridol injection, a low-osmolal magnetic resonance imaging contrast agent. Invest Radiol 27(Suppl 1):S16–S21PubMedGoogle Scholar
  17. Chung WS, Kim MJ, Chung YE et al (2011) Comparison of gadoxetic acid-enhanced dynamic imaging and diffusion-weighted imaging for the preoperative evaluation of colorectal liver metastases. J Magn Reson Imaging 34:345–353PubMedGoogle Scholar
  18. Colosimo C, Ruscalleda J, Korves M et al (2001) Detection of intracranial metastases: a multicenter, intrapatient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dosage. Invest Radiol 36:72–81PubMedGoogle Scholar
  19. Colosimo C, Knopp MV, Barreau X et al (2004) A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours. Neuroradiology 46:655–665PubMedGoogle Scholar
  20. Cotton F (2006) Diffusion-perfusion in intra-axial brain tumors with high relaxivity contrast agents. Neuroradiology 48(Suppl 1):34–40Google Scholar
  21. De Haen C (2001) Conception of the first magnetic resonance imaging contrast agents: a brief history. Top Magn Reson Imaging 12:221–230PubMedGoogle Scholar
  22. Demaerel P, Marchal G, Wilms G et al (1994) Gadodiamide injection at 0.1 and 0.3 mmol/kg body weight: a phase III double-blind, parallel, randomised clinical investigation of known or suspected central nervous system lesions at 1.5T. Neuroradiology 36:355–359PubMedGoogle Scholar
  23. De Cobelli F, Esposito A, Perseghin G et al (2012) Intraindividual comparison of gadobutrol and gadopentetate dimeglumine for detection of myocardial late enhancement in cardiac MRI. AJR Am J Roentgenol 198:809–816PubMedGoogle Scholar
  24. Deray G, Rouviere O, Bacigalupo L et al (2013) Safety of meglumine gadoterate (Gd-DOTA) enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study). Eur Radiol 23:1250–1259Google Scholar
  25. Di Martino M, Marin D, Guerrisi A et al (2010) Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the detection of hepatocellular carcinoma in patients with cirrhosis. Radiology 256:806–816PubMedGoogle Scholar
  26. Duarte JA, Furtado AP, Marroni CA (2012) Use of pineapple juice with gadopentetate dimeglumine as a negative oral contrast for magnetic resonance cholangiopancreatography: a multicentric study. Abdom Imaging 37:447–456PubMedGoogle Scholar
  27. Ekholm SE, Jonsson E, Sandvik L et al (1996) Tolerance and efficacy of Omniscan (gadodiamide injection) in MR imaging of the central nervous system. Acta Radiol 37:223–228PubMedGoogle Scholar
  28. Ekholm SE, Björk-Eriksson T, Western A et al (2001) MRI staging using gadodiamide for soft-tissue tumors of the head and neck region. Results from a phase II trial and a 5-year clinical follow-up. Eur J Radiol 39:168–175PubMedGoogle Scholar
  29. Eldevik OP, Brunberg JA (1994) Gadopentetate dimeglumine- enhanced MR of the brain: clinical utility and safety in patients younger than two years of age. AJNR Am J Neuroradiol 15:1001–1008PubMedGoogle Scholar
  30. Elster AD (1990) Cranial MR imaging with Gd-DTPA in neonates and young infants: preliminary experience. Radiology 176:225–230PubMedGoogle Scholar
  31. Elster AD, Rieser GD (1989) Gd-DTPA-enhanced cranial MR imaging in children: initial clinical experience and recommendations for its use. AJR Am J Roentgenol 153:1265–1268PubMedGoogle Scholar
  32. Emond S, Brunelle F (2011) Gd-DOTA administration at MRI in children younger than 18 months of age: immediate adverse reactions. Pediatr Radiol 41:1401–1406PubMedGoogle Scholar
  33. Essig M, Hartmann M, Lodemann KP et al (2001) Comparison of contrast behavior of gadobenate-dimeglumine and Gd-DTPA in intra-axial brain tumors. A double-blind randomized intraindividual cross-over study [in German]. Radiologe 41:1063–1071PubMedGoogle Scholar
  34. Essig M, Lodemann KP, LeHuu M et al (2002) Comparison of MultiHance and Gadovist for cerebral MR perfusion imaging in healthy volunteers [in German]. Radiologe 42:909–915PubMedGoogle Scholar
  35. Essig M, Lodemann KP, Le-Huu M et al (2006a) Intraindividual comparison of gadobenate dimeglumine and gadobutrol for cerebral magnetic resonance perfusion imaging at 1.5 T. Invest Radiol 41:256–263PubMedGoogle Scholar
  36. Essig M, Tartaro A, Tartaglione T et al (2006b) Enhancing lesions of the brain: intrain- dividual crossover comparison of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators. Acad Radiol 13:744–751PubMedGoogle Scholar
  37. Fink C, Puderbach M, Ley S et al (2004) Contrast-enhanced three-dimensional pulmonary perfusion magnetic resonance imaging: intraindividual comparison of 1.0 M gadobutrol and 0.5 M Gd-DTPA at three dose levels. Invest Radiol 39:143–148PubMedGoogle Scholar
  38. Frydrychowicz A, Lubner MG, Brown JJ et al (2012a) Hepatobiliary MR imaging with gadolinium-based contrast agents. J Magn Reson Imaging 35:492–511PubMedPubMedCentralGoogle Scholar
  39. Frydrychowicz A, Jedynak AR, Kelcz F et al (2012b) Gadoxetic acid-enhanced T1-weighted MR cholangiography in primary sclerosing cholangitis. J Magn Reson Imaging 36:632–640PubMedPubMedCentralGoogle Scholar
  40. Garovic VD, Achauer MA, Kittner T et al (2010) Comparison of gadodiamide-enhanced MR angiography to intra-arterial digital subtraction angiography for evaluation of renal artery stenosis: results of a phase III multicenter trial. J Magn Reson Imaging 31:390–397PubMedGoogle Scholar
  41. Gerretsen SC, le Maire TF, Miller S et al (2010) Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for MR angiography of peripheral arteries. Radiology 255:988–1000PubMedGoogle Scholar
  42. Goshima S, Kanematsu M, Watanabe H et al (2010) Hepatic hemangioma and metastasis: differentiation with gadoxetate disodium-enhanced 3-T MRI. AJR Am J Roentgenol 195:941–946PubMedGoogle Scholar
  43. Goyen M, Debatin JF (2004) Gadopentetate dimeglumine- enhanced three-dimensional MR-angiography: dosing, safety, and efficacy. J Magn Reson Imaging 19:261–273PubMedGoogle Scholar
  44. Goyen M, Lauenstein TC, Herborn CU et al (2001) 0.5 M Gd chelate (Magnevist) versus 1.0 M Gd chelate (Gadovist): dose-independent effect on image quality of pelvic three-dimensional MR-angiography. J Magn Reson Imaging 14:602–607PubMedGoogle Scholar
  45. Goyen M, Herborn CU, Vogt FM et al (2003) Using a 1 M Gd-chelate (gadobutrol) for total-body three-dimensional MR angiography: preliminary experience. J Magn Reson Imaging 17:565–571PubMedGoogle Scholar
  46. Grazioli L, Bondioni MP, Haradome H et al (2012) Hepatocellular adenoma and focal nodular hyperplasia: value of gadoxetic acid-enhanced MR imaging in differential diagnosis. Radiology 262:520–529PubMedGoogle Scholar
  47. Greco A, Parker JR, Ratcliffe CG et al (2001) Phase III, randomized, double-blind, cross-over comparison of gadoteridol and gadopentetate dimeglumine in magnetic resonance imaging of patients with intracranial lesions. Australas Radiol 45:457–463PubMedGoogle Scholar
  48. Grossman RI, Kuhn MJ, Maravilla K et al (1998) Multicenter evaluation of the safety, tolerance, and efficacy of OptiMARK in magnetic resonance imaging of the brain and spine. Acad Radiol 5(Suppl 1):S154–S155 (discussion S156)Google Scholar
  49. Grossman RI, Rubin DL, Hunter G et al (2000) Magnetic resonance imaging in patients with central nervous system pathology: a comparison of OptiMARK (Gd-DTPA-BMEA) and Magnevist (Gd-DTPA). Invest Radiol 35:412–419PubMedGoogle Scholar
  50. Gupta RT, Iseman CM, Leyendecker JR et al (2012) Diagnosis of focal nodular hyperplasia with MRI: multicenter retrospective study comparing gadobenate dimeglumine to gadoxetate disodium. AJR Am J Roentgenol 199:35–43PubMedGoogle Scholar
  51. Gupta RT (2013) Evaluation of the biliary tree and gallbladder with hepatocellular MR contrast agents. Curr Probl Diagn Radiol 42:67–76PubMedGoogle Scholar
  52. Ha S, Lee CH, Kim BH et al (2012) Paradoxical uptake of Gd-EOB-DTPA on the hepatobiliary phase in the evaluation of hepatic metastasis from breast cancer: is the “target sign” a common finding ? Magn Reson Imaging 30:1083–1090PubMedGoogle Scholar
  53. Habibi R, Krishnam MS, Lohan DG et al (2008) High-spatial-resolution lower extremity MR angiography at 3.0 T: contrast agent dose comparison study. Radiology 248:680–692PubMedGoogle Scholar
  54. Hammerstingl R, Adam G, Ayuso JR et al (2009) Comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine-enhanced magnetic resonance imaging in five hundred seventy-two patients with known or suspected liver lesions: results of a multicenter, double-blind, interindividual, randomized clinical phase-III trial. Invest Radiol 44(3):168–176PubMedGoogle Scholar
  55. Hanquinet S, Christophe C, Greef DD et al (1996) Clinical evaluation of gadodiamide injection in paediatric MR imaging. Pediatr Radiol 26:806–810PubMedGoogle Scholar
  56. Haustein J, Laniado M, Niendorf HP et al (1993) Triple-dose versus standard-dose gadopentetate dimeglumine: a randomized study in 199 patients. Radiology 186:855–860PubMedGoogle Scholar
  57. Haynes B (1999) Can it work? Does it work? Is it worth it? The testing of healthcare interventions is evolving. BMJ 319:652–653PubMedGoogle Scholar
  58. Hentsch A, Aschauer MA, Balzer JO et al (2003) Gadobutrol- enhanced moving-table magnetic resonance angiography in patients with peripheral vascular disease: a prospective, multi-centre blinded comparison with digital subtraction angiography. Eur Radiol 13:2103–2114PubMedGoogle Scholar
  59. Herborn CU, Lauenstein TC, Ruehm SG et al (2003) Intra-individual comparison of gadopen- tetate dimeglumine, gadobenate dimeglumine, and gad- obutrol for pelvic 3D magnetic resonance angiography. Invest Radiol 38:27–33PubMedGoogle Scholar
  60. Herborn CU, Goyen M, Quick HH et al (2004) Whole-body 3D MR angiography of patients with peripheral arterial occlusive disease. AJR Am J Roentgenol 182:1427–1434PubMedGoogle Scholar
  61. Herborn CU, Runge VM, Watkins DM et al (2008) MR angiography of the renal arteries: intraindividual comparison of double-dose contrast enhancement at 1.5 T with standard dose at 3 T. AJR Am J Roentgenol 190:173–177PubMedGoogle Scholar
  62. Hesselink JR, Healy ME, Press GA, Brahme FJ (1988) Benefits of Gd-DTPA for MR imaging of intracranial abnormalities. J Comput Assist Tomogr 12:266–274PubMedGoogle Scholar
  63. Heverhagen JT, Reitz I, Pavlicova M et al (2007) The impact of the dosage of intravenous gadolinium-chelates on the vascular signal intensity in MR angiography. Eur Radiol 17:626–637PubMedGoogle Scholar
  64. Heverhagen JT, Wright CL, Schmalbrock P et al (2009) Dose comparison of single versus double dose in contrast-enhanced magnetic resonance angiography of the renal arteries: intra-individual cross-over blinded trial using Gd-DTPA. Eur Radiol 19:67–72PubMedGoogle Scholar
  65. Huber S, Muthupillai R, Cheong B et al (2008) Safety of gadoversetamide in patients with acute and chronic myocardial infarction. J Magn Reson Imaging 28:1368–1378PubMedGoogle Scholar
  66. Hwang J, Kim SH, Lee MW, Lee JY (2012) Small (≤2 cm) hepatocellular carcinoma in patients with chronic liver disease: comparison of gadoxetic acid-enhanced 3.0 T MRI and multiphasic 64-multirow detector CT. Br J Radiol 85:e314–e322PubMedGoogle Scholar
  67. Jin YJ, Nah SY, Lee JW et al (2013) Utility of adding Primovist magnetic resonance imaging to analysis of hepatocellular carcinoma by liver dynamic computed tomography. Clin Gastroenterol Hepatol 11:187–192PubMedGoogle Scholar
  68. Jourdan C, Heverhagen JT, Knopp MV (2007) Dose comparison of single- versus double-dose in contrast-enhanced magnetic resonance angiography of the carotid arteries: intraindividual cross-over blinded trial using Gd-DTPA. J Magn Reson Imaging 25:557–563PubMedGoogle Scholar
  69. Kang JW, Lim TH, Choi CG et al (2010) Evaluation of contrast-enhanced magnetic resonance angiography (MRA) using Gd-DOTA compared with time-of-flight MRA in the diagnosis of clinically significant non-coronary arterial disease. Eur Radiol 20:1934–1944PubMedGoogle Scholar
  70. Kang Y, Lee JM, Kim SH, Han JK, Choi BI (2012) Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images. Radiology 264:751–760PubMedGoogle Scholar
  71. Kaplan GD, Aisen AM, Aravapalli SR (1991) Preliminary clinical trial of gadodiamide injection: a new nonionic gadolinium contrast agent for MR imaging. J Magn Reson Imaging 1:57–62PubMedGoogle Scholar
  72. Katakami N, Inaba Y, Sugata S et al (2011) Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase II/III study in patients with known or suspected brain metastases. Invest Radiol 46:411–418PubMedGoogle Scholar
  73. Kim ES, Chang JH, Choi HS et al (2010) Diagnostic yield of double-dose gadobutrol in the detection of brain metastasis: intraindividual comparison with double-dose gadopentetate dimeglumine. AJNR Am J Neuroradiol 31:1055–1058PubMedGoogle Scholar
  74. Kim RJ, Albert TS, Wible JH et al for Gadoversetamide Myocardial Infarction Imaging Investigators (2008) Performance of delayed-enhancement magnetic resonance imaging with gadoversetamide contrast for the detection and assessment of myocardial infarction: an international, multicenter, double-blinded, randomized trial. Circulation 117:629–637Google Scholar
  75. Kim S, Mussi TC, Lee LJ et al (2013) Effect of flip angle for optimization of image quality of gadoxetate disodium-enhanced biliary imaging at 1.5 T. AJR Am J Roentgenol 200:90–96PubMedGoogle Scholar
  76. Kim YK, Lee YH, Kim CS et al (2008) Double-dose 1.0-M gadobutrol versus standard-dose 0.5-M gadopentetate dimeglumine in revealing small hypervascular hepatocellular carcinomas. Eur Radiol 18:70–77PubMedGoogle Scholar
  77. Kim YK, Lee WJ, Park MJ et al (2012a) Hypovascular hypointense nodules on hepatobiliary phase gadoxetic acid-enhanced MR images in patients with cirrhosis: potential of DW imaging in predicting progression to hypervascular HCC. Radiology 265:104–114PubMedGoogle Scholar
  78. Kim YK, Park G, Kim CS et al (2012b) Diagnostic efficacy of gadoxetic acid-enhanced MRI for the detection and characterisation of liver metastases: comparison with multidetector-row CT. Br J Radiol 85:539–547PubMedGoogle Scholar
  79. Knauth M, Forsting M, Hartmann M et al (1996) MR enhancement of brain lesions: increased contrast dose compared with magnetization transfer. AJNR Am J Neuroradiol 17:1853–1859PubMedGoogle Scholar
  80. Knopp MV, Giesel FL, von Tengg-Kobligk H et al (2003) Contrast-enhanced MR angiography of the run-off vasculature: intraindividual comparison of gadobenate dime- glumine with gadopentetate dimeglumine. J Magn Reson Imaging 17:694–702PubMedGoogle Scholar
  81. Knopp MV, Runge VM, Essig M et al (2004) Primary and secondary brain tumors at MR imaging: bicentric intra individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology 230:55–64PubMedGoogle Scholar
  82. Koh DM, Collins DJ, Wallace T et al (2012) Combining diffusion-weighted MRI with Gd-EOB-DTPA-enhanced MRI improves the detection of colorectal liver metastases. Br J Radiol 85:980–989PubMedGoogle Scholar
  83. Krause U, Kroencke T, Spielhaupter E et al (2005) Contrast- enhanced magnetic resonance angiography of the lower extremities: standard-dose versus high-dose gadodiamide injection. J Magn Reson Imaging 21:449–454PubMedGoogle Scholar
  84. Kreitner KF, Kunz RP, Herber S et al (2008) MR angiography of the pedal arteries with gadobenate dimeglumine, a contrast agent with increased relaxivity, and comparison with selective intraarterial DSA. J Magn Reson Imaging 27:78–85PubMedGoogle Scholar
  85. Kroencke TJ, Wasser MN, Pattynama PM et al (2002) Gadobenate dimeglumine-enhanced MR angiography of the abdominal aorta and renal arteries. AJR Am J Roentgenol 179:1573–1582PubMedGoogle Scholar
  86. Kuhn MJ, Picozzi P, Maldjian JA et al (2007) Evaluation of intra-axial enhancing brain tumors on magnetic resonance imaging: intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention. J Neurosurg 106:557–566PubMedGoogle Scholar
  87. Laissy JP, Soyer P, Tebboune D et al (1995) Abdominal aortic aneurysms: assessment with gadolinium-enhanced time-of-flight coronal MR angiography (MRA). Eur J Radiol 20:1–8PubMedGoogle Scholar
  88. Lemke AJ, Sander B, Balzer T et al (1997) Safety and use of gadobutrol in patients with brain tumors (phase III trial) [in German]. RöFo 167:591–598PubMedGoogle Scholar
  89. Lipski S, Baraton J, Mamou Mani T et al (1990) Utilization of gadolinium DOTA in the diagnosis of tumors of the central nervous system of the child. Diagn Interv Radiol 2:163–167Google Scholar
  90. Lowe LH, Kearns GL, Wible JH Jr (2006) The safety and efficacy of neuroimaging with gadoversetamide injection in pediatric patients. Curr Med Res Opin 22:2515–2524PubMedGoogle Scholar
  91. Lundby B, Gordon P, Hugo F (1996) MRI in children given gadodiamide injection: safety and efficacy in CNS and body indications. Eur J Radiol 23:190–196PubMedGoogle Scholar
  92. Maravilla KR, Maldjian JA, Schmalfuss IM et al (2006) Contrast enhancement of central nervous system lesions: multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology 240:389–400PubMedGoogle Scholar
  93. Marin D, Di Martino M, Guerrisi A et al (2009) Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumine-enhanced MR imaging and multiphasic 64-section CT. Radiology 251:85–95PubMedGoogle Scholar
  94. Marti-Bonmati L, Vega T, Benito C et al (2000) Safety and efficacy of Omniscan (gadodiamide injection) at 0.1 mmol/kg for MRI in infants younger than 6 months of age: phase III open multicenter study. Invest Radiol 35:141–147PubMedGoogle Scholar
  95. Martincich L, Faivre-Pierret M, Zechmann CM et al (2011) Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for breast MR imaging (DETECT Trial). Radiology 258:396–408PubMedGoogle Scholar
  96. Mayr NA, Yuh WT, Muhonen MG et al (1994) Cost-effectiveness of high-dose MR contrast studies in the evaluation of brain metastases. AJNR Am J Neuroradiol 15:1053–1061PubMedGoogle Scholar
  97. McLachlan SJ, Francisco JC, Pernicone JR, Hasso AN (1994) Efficacy evaluation of gadoteridol for MR angiography of intracranial vascular lesions. J Magn Reson Imaging 4:405–411PubMedGoogle Scholar
  98. Mohrs OK, Oberholzer K, Krummenauer F et al (2004) Comparison of contrast-enhanced MR angiography of the aortoiliac vessels using a 1.0 molar contrast agent at 1.0 T with intra-arterial digital subtraction angiography [in German]. RöFo 176:985–991PubMedGoogle Scholar
  99. Morana G, Grazioli L, Kirchin MA et al (2011) Solid hypervascular liver lesions: accurate identification of true benign lesions on enhanced dynamic and hepatobiliary phase magnetic resonance imaging after gadobenate dimeglumine administration. Invest Radiol 46:225–239PubMedGoogle Scholar
  100. Motosugi U, Ichikawa T, Onohara K et al (2011) Distinguishing hepatic metastasis from hemangioma using gadoxetic acid-enhanced magnetic resonance imaging. Invest Radiol 46:359–365PubMedGoogle Scholar
  101. Myhr G, Rinck PA, Borseth A (1992) Gadodiamide injection and gadopentetate dimeglumine. A double-blind study in MR imaging of the CNS. Acta Radiol 33:405–409PubMedGoogle Scholar
  102. Norén B, Forsgren MF, Dahlqvist Leinhard O et al (2013) Separation of advanced from mild hepatic fibrosis by quantification of the hepatobiliary uptake of Gd-EOB-DTPA. Eur Radiol 23:174–181PubMedGoogle Scholar
  103. Oudkerk M, Sijens PE, Van Beek EJ, Kuijpers TJ (1995) Safety and efficacy of Dotarem (Gd-DOTA) versus Magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system. Invest Radiol 30:75–78PubMedGoogle Scholar
  104. Parizel PM, Degryse HR, Gheuens J et al (1989) Gadolinium- DOTA enhanced MR imaging of intracranial lesions. J Comput Assist Tomogr 13:378–385PubMedGoogle Scholar
  105. Pediconi F, Kubik-Huch R, Chilla B et al (2013) Intra-individual randomised comparison of gadobutrol 1.0 M versus gadobenate dimeglumine 0.5 M in patients scheduled for preoperative breast MRI. Eur Radiol 23:84–92PubMedGoogle Scholar
  106. Pennekamp W, Roggenland D, Hering S et al (2011) Intra-individual, randomised comparison of the MRI contrast agents gadobutrol and gadoterate in imaging the distal lower limb of patients with known or suspected osteomyelitis, evaluated in an off-site blinded read. Eur Radiol 21:1058–1067PubMedGoogle Scholar
  107. Prokop M, Schneider G, Vanzulli A et al (2005) Contrast- enhanced MR Angiography of the renal arteries: blinded multicenter crossover comparison of gadobenate dimeglumine andgadopentetate dimeglumine. Radiology 234:399–408PubMedGoogle Scholar
  108. Purysko AS, Remer EM, Coppa CP et al (2012) Characteristics and distinguishing features of hepatocellular adenoma and focal nodular hyperplasia on gadoxetate disodium-enhanced MRI. AJR Am J Roentgenol 198:115–123PubMedGoogle Scholar
  109. Rasmus M, Bremerich J, Egelhof T et al (2008) Total-body contrast-enhanced MRA on a short, wide-bore 1.5-T system: intra-individual comparison of Gd-BOPTA and Gd-DOTA. Eur Radiol 18:2265–2273PubMedGoogle Scholar
  110. Rubin DL, Desser TS, Semelka R et al (1999) A multicenter, randomized, double-blind study to evaluate the safety, tol- erability, and efficacy of OptiMARK (gadoversetamide injection) compared with Magnevist (gadopentetate dimeglumine) in patients with liver pathology: results of a Phase III clinical trial. J Magn Reson Imaging 9:240–250PubMedGoogle Scholar
  111. Rumboldt Z, Rowley HA, Steinberg F et al (2009) Multicenter, double-blind, randomized, intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in MRI of brain tumors at 3 tesla. J Magn Reson Imaging 29:760–767PubMedPubMedCentralGoogle Scholar
  112. Runge VM, Schaible TF, Goldstein HA et al (1988) Gd-DTPA. Clinical efficacy. Radiographics 8:147–159PubMedGoogle Scholar
  113. Runge VM, Gelblum DY, Pacetti ML et al (1990) Gd-HP-DO3A in clinical MR imaging of the brain. Radiology 177:393–400PubMedGoogle Scholar
  114. Runge VM, Bradley WG, Brant-Zawadzki MN et al (1991a) Clinical safety and efficacy of gadoteridol: a study in 411 patients with suspected intracranial and spinal disease. Radiology 181:701–709PubMedGoogle Scholar
  115. Runge VM, Dean B, Lee C et al (1991b) Phase III clinical evaluation of Gd-HP-DO3A in head and spine disease. J Magn Reson Imaging 1:47–56PubMedGoogle Scholar
  116. Runge VM, Kirsch JE, Burke VJ et al (1992) High-dose gadoteridol in MR imaging of intracranial neoplasms. J Magn Reson Imaging 2:9–18PubMedGoogle Scholar
  117. Runge VM, Armstrong MR, Barr RG et al (2001) A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology. Invest Radiol 36:65–71PubMedGoogle Scholar
  118. Runge VM, Parker JR, Donovan M (2002) Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain. Invest Radiol 37:269–280PubMedGoogle Scholar
  119. Russell EJ, Schaible TF, Dillon W et al (1989) Multicenter doubleblind placebo-controlled study of gadopentetate dimeglumine as an MR contrast agent: evaluation in patients with cerebral lesions. AJR Am J Roentgenol 152:813–823PubMedGoogle Scholar
  120. Sano K, Ichikawa T, Motosugi U et al (2011) Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology 261:834–844PubMedGoogle Scholar
  121. Schäfer FK, Schäfer PJ, Jahnke T et al (2003) First clinical results in a study of contrast enhanced magnetic resonance angiography with the 1.0 molar gadobutrol in peripheral arterial occlusive disease—comparison to intra-arterial DSA [in German]. RöFo 175:556–564PubMedGoogle Scholar
  122. Schäfer FK, Schäfer PJ, Altjohann C et al (2007) A multicenter, site-independent, blinded study to compare the diagnostic accuracy of contrast-enhanced magnetic resonance angiography using 1.0 M gadobutrol (Gadovist) to intra-arterial digital subtraction angiography in body arteries. Eur J Radiol 61:315–323Google Scholar
  123. Schäfer PJ, Boudghene FP, Brambs HJ et al (2006) Abdominal and iliac arterial stenoses: comparative double-blinded randomized study of diagnostic accuracy of 3D MR angiography with gadodiamide or gadopentetate dimeglumine. Radiology 238:827–840Google Scholar
  124. Schneider G, Kirchin MA, Pirovano G et al (2001) Gadobenate dimeglumine-enhanced magnetic resonance imaging of intracranial metastases: effect of dose on lesion detection and delineation. J Magn Reson Imaging 14:525–539PubMedGoogle Scholar
  125. Schneider G, Ballarati C, Grazioli L et al (2007) Gadobenate dimeglumine-enhanced MR angiography: diagnostic performance of four doses for detection and grading of carotid, renal, and aorto-iliac stenoses compared to digital subtraction angiography. J Magn Reson Imaging 26:1020–1032PubMedGoogle Scholar
  126. Seidl Z, Vymazal J, Mechl M et al (2012) Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study). AJNR Am J Neuroradiol 33:1050–1058PubMedGoogle Scholar
  127. Seo HJ, Kim MJ, Lee JD, Chung WS, Kim YE (2011) Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases. Invest Radiol 46:548–555PubMedGoogle Scholar
  128. Soulez G, Pasowicz M, Benea G et al (2008) Renal artery stenosis evaluation: diagnostic performance of gadobenate dimeglumine-enhanced MR Angiography-comparison with DSA. Radiology 247:273–285PubMedGoogle Scholar
  129. Stack JP, Antoun NM, Jenkins JP et al (1988) Gadolinium-DTPA as a contrast agent in magnetic resonance imaging of the brain. Neuroradiology 30:145–154PubMedGoogle Scholar
  130. Stimac GK, Porter BA, Olson DO et al (1988) Gadolinium-DTPA-enhanced MR imaging of spinal neoplasms: preliminary investigation and comparison with unenhanced spin-echo and STIR sequences. AJR Am J Roentgenol 151:1185–1192PubMedGoogle Scholar
  131. Sze G, Johnson C, Kawamura Y et al (1990) Comparison of single- and triple-dose contrast MR contrast agent: evaluation in patients with spinal tumors. AJNR Am J Neuroradiol 11:967–974PubMedGoogle Scholar
  132. Sze G, Brant-Zawadzki M, Haughton VM et al (1991) Multicenter study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine. Radiology 181:693–699PubMedGoogle Scholar
  133. Sze G, Stimac GK, Bartlett C et al (1998) Multicenter study of gadopentetate dimeglumine as an material in the MR screening of brain metastases. AJNR Am J Neuroradiol 19:821–828PubMedGoogle Scholar
  134. Tamada T, Ito K, Yamamoto A et al (2011) Hepatic hemangiomas: evaluation of enhancement patterns at dynamic MRI with gadoxetate disodium. AJR Am J Roentgenol 196:824–830PubMedGoogle Scholar
  135. Thilmann O, Larsson EM, Björkman-Burtscher IM et al (2005) Comparison of contrast agents with high molarity and with weak protein binding in cerebral perfusion imaging at 3 T. J Magn Reson Imaging 22:597–604PubMedGoogle Scholar
  136. Thurnher S, Miller S, Schneider G et al (2007) Diagnostic performance of gadobenate dimeglumine enhanced MR angiography of the iliofemoral and calf arteries: a large-scale multicenter trial. AJR Am J Roentgenol 189:1223–1237PubMedGoogle Scholar
  137. Tombach B, Benner T, Reimer P et al (2003) Do highly concentrated gadolinium chelates improve MR brain perfusion imaging? Intraindividually controlled randomized crossover concentration comparison study of 0.5 versus 1.0 mol/L gadobutrol. Radiology 226:880–888PubMedGoogle Scholar
  138. Tombach B, Bohndorf K, Brodtrager W et al (2008) Comparison of 1.0 M gadobutrol and 0.5 M gadopentate dimeglumine-enhanced MRI in 471 patients with known or suspected renal lesions: results of a multicenter, single blind, interindividual, randomized clinical phase III trial. Eur Radiol 18:2610–2619PubMedGoogle Scholar
  139. Valk J, Algra PR, Hazenberg CJ, Slooff WB, Svaland MG (1993) A double-blind, comparative study of gadodiamide injection and gadopentetate dimeglumine in MRI of the central nervous system. Neuroradiology 35:173–177PubMedGoogle Scholar
  140. Van Dijk P, Sijens PE, Schmitz PI et al (1997) Gd-enhanced MR imaging of brain metastases: contrast as a function of dose and lesion size. Magn Reson Imaging 15:535–541PubMedGoogle Scholar
  141. Vogl TJ, Friebe CE, Balzer T et al (1995) Diagnosis of cerebral metastasis with standard dose gadobutrol versus a high dose protocol. Intraindividual evaluation of a phase II high dose study [in German]. Radiologe 35:508–516PubMedGoogle Scholar
  142. Von Tengg-Kobligk H, Floemer F, Knopp MV (2003) Multiphasic MR angiography as an intra-individual comparison between the contrast agents Gd-DTPA, Gd-BOPTA, and Gd-BT-DO3A [in German]. Radiologe 43:171–178Google Scholar
  143. Wagner M, Schilling R, Doeblin P et al (2013) Macrocyclic contrast agents for magnetic resonance imaging of chronic myocardial infarction: intraindividual comparison of gadobutrol and gadoterate meglumine. Eur Radiol 23:108–114PubMedGoogle Scholar
  144. Wikström J, Wasser MN, Pattynama PM et al (2003) Gadobenate dimeglumine-enhanced magnetic resonance angiography of the pelvic arteries. Invest Radiol 38:504–515PubMedGoogle Scholar
  145. Wyttenbach R, Gianella S, Alerci M et al (2003) Prospective blinded evaluation of Gd-DOTA- versus Gd-BOPTA-enhanced peripheral MR angiography, as compared with digital subtraction angiography. Radiology 227:261–269PubMedGoogle Scholar
  146. Yuh WT, Engelken JD, Muhonen MG et al (1992) Experience with high-dose gadolinium MR imaging in the evaluation of brain metastases. AJNR Am J Neuroradiol 13:335–345PubMedGoogle Scholar
  147. Yuh WT, Fisher DJ, Runge VM et al (1994) Phase III multicenter trial of high-dose gadoteridol in MR evaluation of brain metastases. AJNR Am J Neuroradiol 15:1037–1051PubMedGoogle Scholar
  148. Yuh WT, Tali ET, Nguyen HD et al (1995) The effect of contrast dose, imaging time, and lesion size in the MR detection of intracerebral metastasis. AJNR Am J Neuroradiol 16:373–380 (Erratum in: AJNR Am J Neuroradiol 16:1384)Google Scholar
  149. Zech CJ, Bartolozzi C, Bioulac-Sage P et al (2013) Consensus report of the fifth international forum for liver MRI. AJR Am J Roentgenol 201:97–107Google Scholar
  150. Zoarski GH, Lufkin RB, Bradley WG Jr et al (1993) Multicenter trial of gadoteridol, a nonionic gadolinium chelate, in patients with suspected head and neck pathology. AJNR Am J Neuroradiol 14:955–961PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of Radiology, C-2SLeiden University Medical CenterZA LeidenThe Netherlands

Personalised recommendations